Company’s
The Company’s focus at booth 7 will be its innovative Portable Neuromodulation Stimulator (PoNS®), an orally applied therapy delivered by translingual neurostimulation to improve gait deficit in people with multiple sclerosis (“MS”). On site to discuss PoNS, the science of neuromodulation and how PoNS leverages electrical stimulation with physical rehabilitation to improve the ability of those living with MS to walk will be Helius’ Director of Physical Therapy,
Helius’ debut at the conference is timely, coming just after National Rehabilitation Awareness Week (
“The calendar is spotlighting rehabilitation and physical therapy right now, and we’re enthused to keep the conversation going with ANPT conference attendees,” said Helius’ Chief Medical Officer,
PoNS Therapy promotes neuromodulation of specific areas in the brainstem and cerebral cortex of people with MS. It works by delivering mild electrical impulses to branches of the trigeminal and facial nerves in the tongue while users perform a set of gait and balance rehabilitation exercises as instructed by a physical therapist. When used regularly and consistently over the 14-week treatment period, PoNS triggers neuroplastic mechanisms that can lead to significant improvement in gait function.
“Neurologic physical therapists are a highly specialized subset within the physical therapy community, and they have an outsized impact when it comes to adopting new technologies and approaches that can help people with MS,” Favit-Van Pelt said. “The opportunity to have one-on-one conversations with these experts in a focused conference environment allows us to expand on the importance of PoNS accessibility in promoting neuroplasticity and enhance MS patients’ likelihood to walk better.”
About
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in
PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in
Cautionary Disclaimer Statement
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, disruptions in the banking system and financial markets, lingering impacts of the COVID-19 pandemic, the effect of macroeconomic conditions and the Company’s ability to access capital markets, the Company’s ability to train physical therapists in the supervision of the use of the PoNS Treatment, the Company’s ability to secure contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, secure state distribution licenses, build a commercial team and build relationships with Key Opinion Leaders, neurology experts and neurorehabilitation centers, market awareness of the PoNS device, availability of funds, manufacturing, labor shortage and supply chain risks, our ability to maintain and enforce our intellectual property rights, clinical trials and the clinical development process, the product development process, the regulatory submission review and approval process, our operating costs and use of cash, and our ability to achieve significant revenues, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended
The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
Investor Relations Contact
T: 212-452-2793
E: lwilson@insitecony.com
Source:
2023 GlobeNewswire, Inc., source